How much funding has Innoregen raised?

Innoregen has raised $4.5M in total funding. Key investors include Korea Investment Partners; Daily Venture Capital; Company K Partners; Smilegate Investment; UTC Investment.

Who is the CEO of Innoregen?

Park Dae-jin is the CEO of Innoregen. The company was founded in 2018.

Where is Innoregen located?

Innoregen is headquartered in South Korea.

What funding stage is Innoregen at?

Innoregen is currently at the Active stage.

How many employees does Innoregen have?

Innoregen has approximately 11-50 employees.

Innoregen

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

MaterialsSouth KoreaFounded 2018· One of 961 Materials companies tracked by AMPulse

Develops bioinks and hydrogels for 3D bioprinting of artificial organs and regenerative medicine applications.

CEO / Founder: Park Dae-jin
Team Size: 11-50
Stage: Active
Total Funding: $4.5M
Latest Round: Series A
Key Investors: Korea Investment Partners; Daily Venture Capital; Company K Partners; Smilegate Investment; UTC Investment

Technology & Products

Key Products

Bioinks (human-derived gelatin, collagen, extracellular matrices, hydrogels), 3D tissue models, consulting services in 3D bioprinting, artificial organs, regenerative medicine applications.

Technological Advantage

First Korean developer of bioinks combining human-derived collagen and extracellular matrix (ECM) with hydrogels, optimizing the microenvironment for cell proliferation and differentiation in artificial organ production.

Differentiation

Value Proposition

Enables the production of artificial organs and tissues using human-derived collagen and ECM-based bioinks, representing the first such capability in the Korean market.

How They Differentiate

Differentiates through the use of human-derived materials rather than synthetic or animal-based alternatives, providing higher biocompatibility and more accurate physiological modeling for artificial organ development and drug testing.

Market & Competition

Target Customers

Research Universities; Regenerative Medicine Companies; Pharmaceutical R&D Centers; Hospitals

Industry Verticals

Medical; Regenerative Medicine

Competitors

T&R Biofab

Growth & Milestones

Growth Metrics

Raised $4.5M (5B KRW) Series A in 2021; Developed Korea's first human-derived collagen bioink; Established a dedicated GMP-certified production facility for medical-grade bioinks

Major Milestones

Developed high-functionality bioink for regenerative medicine; Established global sales partnership with German bio-instrument company GeSiM

Notable Customers

Wake Forest Institute for Regenerative Medicine (joint establishment of an institute)

https://www.innoregen.com

Why this company matters

Innoregen occupies a distinctive position in the Korean bioprinting materials market as the first domestic developer of bioinks that combine human-derived collagen and extracellular matrix (ECM) with hydrogels. Founded in 2018, the company addresses a critical gap in regenerative medicine: the need for biocompatible, standardized bioinks that can support cell proliferation and differentiation during the fabrication of artificial tissues and organs. By using human-derived rather than synthetic or animal-based materials, Innoregen claims higher biocompatibility and more accurate physiological modeling for downstream applications.

The company's core product line includes bioinks formulated from human-derived gelatin, collagen, ECM, and hydrogels, as well as 3D tissue models and consulting services for bioprinting and regenerative medicine. These materials are optimized for extrusion-based bioprinting processes and are produced in a dedicated GMP-certified facility to ensure medical-grade quality. Innoregen's technological advantage lies in its ability to tune the microenvironment for cell growth, a factor critical for both artificial organ production and pharmaceutical drug testing.

Target customers include research universities, regenerative medicine companies, pharmaceutical R&D centers, and hospitals. Notably, Innoregen has established a joint institute with the Wake Forest Institute for Regenerative Medicine, a globally recognized leader in the field. The company also partners with GeSiM, a German bio-instrument firm, for global sales and distribution. Competitors in the Korean market include T&R Biofab, though Innoregen differentiates through its exclusive focus on human-derived ECM bioinks.

Innoregen raised a $4.5 million Series A round in 2021 from investors including Korea Investment Partners, Daily Venture Capital, Company K Partners, Smilegate Investment, and UTC Investment. The company's key milestones include developing Korea's first human-derived collagen bioink and establishing a GMP-certified production facility. A strategic open question is whether its bioinks can scale from research-grade volumes to clinical-grade production for actual organ transplantation, a hurdle that will determine its long-term relevance in the regenerative medicine supply chain.